11 Search Results

q=Speaking%20engagements

Search Again


Shreeram Akilesh , MD, PhD

Email: shreeram@uw.edu

Phone: (206) 598-6408

Dr. Akilesh is presently applying next generation genomic tools and analyses to understand the development, structure and function of the kidney and its component cells in health and disease.

View Bio

Susan Bullman , PhD

Email: sbullman@fredhutch.org

Phone: (206) 667-3449

The Bullman Lab focuses firstly on understanding the translational impact of the tumor microbiota in human cancers, and secondly on the delineation of specific mechanisms involved in the pathogenesis of microbe-associated human cancers. They combine molecular microbiology, computational biology, biochemistry, and genetics to understand host-microbial interactions within the tumor microenvironment. Through such efforts, her lab seeks to make discoveries that have both a scientific and clinical impact in the emerging area of bacterial-associated malignancies. Bacterial agents that have a role in cancer initiation or progression provide a viable route for prevention and treatment of these cancers.

View Bio

Victor Chow , MD

Email: vchow@fredhutch.org

Phone: (206) 667-7731

Dr. Chow conducts clinical research in lymphoma utilizing combination approaches with cellular-based therapies.

View Bio

Jordan Gauthier , MD, MSc

Email: jgauthier@fredhutch.org

Phone: (206) 667-2713

Much of Dr. Gauthier's research has been focused on improving outcomes for patients treated with BMT or CAR T-cell therapy. Through his work, he has identified factors that can help predict the success of CAR T-cell therapy for patients who have leukemia and lymphoma.

View Bio

Taran Gujral , PhD, Msc

Email: tgujral@fredhutch.org

Phone: (206) 667-4149

Cells respond to external stimuli by activating nonlinear and highly interconnected networks of signaling proteins. Dr. Gujral's work focuses on understanding how these networks are wired in different cell types and how they influence response to growth factors or cytotoxic agents using both hypothesis driven and systems-based data-driven approaches. His lab combines approaches from molecular genetics with cell and systems biology to study a recently discovered Wnt5-Fzd2 signaling pathway in metastasis as well as cell-to-cell contact in regulating cell fate decisions.

View Bio

Evan Hall , MD, MPhil

Email: evanh@seattlecca.org

Phone: (206) 606-2496

Dr. Hall's research focuses on how to measure and improve quality of life for patients with cancer. His other areas of interest include physician-patient communication, the health economics of cancer and the benefits of novel modes of patient and caregiver social support, such as online communities.

View Bio

George Ioannou , B.M.B.Ch, MS, FAASLD

Email: George.Ioannou@va.gov

Dr. Ioannou's clinical and research interests include liver cancer, hepatitis C, non-alcoholic fatty liver disease, iron deficiency and iron overload.

View Bio

Ryan Lynch , MD

Email: rclynch@uw.edu

Phone: (206) 606-1739

Dr. Lynch conducts clinical trials to optimize treatments and bring novel therapeutic agents to the clinic for patients with lymphomas and chronic lymphocytic leukemia.

View Bio

Lucas Sullivan , PhD

Email: lucas@fredhutch.org

Phone: (206) 667-7826

Dr. Lucas Sullivan studies cell metabolism under normal and cancerous conditions. He also aims to deepen the understanding of metabolism in general, working to discover new molecular products of metabolism and their roles in sustaining cell survival and growth. The current goals of the lab seek to span from translationally relevant projects, testing metabolism modifying therapies in preclinical cancer models, to basic science discovery, investigating new roles for coenzyme networks and identifying new metabolites, to better understand cell metabolism in cancer and beyond.

View Bio

Chaitra Ujjani , MD

Email: ujjani@uw.edu

Phone: (206) 606-1955

Dr. Ujjani has designed and led multi-center clinical trials that test new drug combinations for treating lymphomas and chronic lymphocytic leukemia (CLL), with the goals of more precisely targeting cancer while decreasing the intensity of side effects. She is also interested in immunotherapy and novel therapeutics for B-cell lymphoma and CLL.

View Bio

Takuma Uo , Ph.D.

Email: tuo@uw.edu

Phone: 206-897-5463

Age is the most common risk factor for prostate cancer, with the rapid rise in its incidence after age 50. As a member of the prostate cancer research group in Division of Gerontology and Geriatric Medicine, Dr. Uo is focused on understanding molecular logics behind adaptive resistance of prostate cancer cells to the most forefront androgen-targeted therapies. Specifically, his research program examines the cell autonomous and nonautonomous mechanisms that enable prostate cancer progression, including the constitutively-active isoforms of androgen receptor, the metabolic rewiring, and the extracellular fuel supply from tumor microenvironment and adipose tissues. He harnesses in-depth knowledge and advanced technologies of molecular, cellular, chemical, synthetic, and computational biology to help develop next-generation of therapeutics to improve patient survival.

View Bio